SAFETY DATA SHEET

Lisinopril Formulation

SECTION 1. IDENTIFICATION

Product name : Lisinopril Formulation

Manufacturer or supplier’s details

Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Combustible dust

Reproductive toxicity : Category 1A

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney)

GHS label elements

Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H360D May damage the unborn child.
H373 May cause damage to organs (Kidney) through prolonged or repeated exposure if swallowed.

Precautionary Statements

Prevention: P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response: P308 + P313 IF exposed or concerned: Get medical advice/ attention.
SAFETY DATA SHEET

Lisinopril Formulation

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
</tbody>
</table>

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

2 / 13
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides
Metal oxides
Oxides of phosphorus

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>5 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total)</td>
<td>10 mg/m³</td>
<td>NIOSH REL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total dust)</td>
<td>15 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable fraction)</td>
<td>5 mg/m³</td>
<td>OSHA Z-1</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>TWA</td>
<td>40 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>400 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Engineering measures:**
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
- If sufficient ventilation is unavailable, use with local exhaust
ventilation. Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m$^3$ - total dust, 5 mg/m$^3$ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m$^3$ - respirable particles, 10 mg/m$^3$ - inhalable particles.

**Personal protective equipment**

**Respiratory protection**
- General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**
- **Material**: Chemical-resistant gloves
- **Remarks**: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Eye protection**
- Wear the following personal protective equipment: Safety goggles

**Skin and body protection**
- Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Hygiene measures**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance**: powder

**Color**: No data available
Odor: odorless
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: No data available
Relative vapor density: No data available
Density: No data available
Solubility(ies)
   Water solubility: No data available
Partition coefficient: n-octanol/water
   Autoignition temperature: No data available
Decomposition temperature: No data available
Viscosity
   Viscosity, dynamic: No data available
   Viscosity, kinematic: No data available
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available
SAFETY DATA SHEET

Lisinopril Formulation

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Starch:
Acute oral toxicity: LD50 (Mouse): > 5,000 mg/kg

Lisinopril:
Acute oral toxicity: LD50 (Rat): > 20,000 mg/kg
LD50 (Mouse): > 20,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Lisinopril:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Lisinopril:
Species: Rabbit
Result: Mild eye irritation
Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Lisinopril:
Test Type: Maximization Test
Routes of exposure: Dermal
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Lisinopril:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: Alkaline elution assay
  Test system: rat hepatocytes
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Application Route: Oral
  Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Lisinopril:
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
NOAEL: 90 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
NOAEL: 135 mg/kg body weight
Result: negative
SAFETY DATA SHEET

Lisinopril Formulation

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
May damage the unborn child.

Components:

Lisinopril:

Effects on fertility:
- Test Type: Fertility
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 300 mg/kg body weight
  - Symptoms: No effects on mating performance.
  - Result: Animal testing did not show any effects on fertility.

Effects on fetal development:
- Test Type: Development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 30 mg/kg body weight
  - Result: positive, No teratogenic effects.

  - Test Type: Development
    - Species: Mouse
    - Application Route: Oral
    - Developmental Toxicity: LOAEL: 100 mg/kg body weight
    - Symptoms: Total Resorptions / resorption rate.
    - Result: Embryotoxic effects and adverse effects on the offspring were detected.

  - Test Type: Development
    - Species: Rabbit
    - Application Route: Oral
    - Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
    - Result: Embryotoxic effects and adverse effects on the offspring were detected.

Reproductive toxicity - Assessment:
Positive evidence of adverse effects on development from human epidemiological studies.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Kidney) through prolonged or repeated exposure if swallowed.
Components:
Lisinopril:
Routes of exposure : Ingestion
Target Organs : Kidney
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:
Lisinopril:
Species : Rat
LOAEL : < 3,650 mg/kg
Application Route : Oral
Exposure time : 1 y
Target Organs : Kidney

Species : Dog
LOAEL : < 840 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure
Components:
Lisinopril:
Ingestion : Symptoms: Dizziness, Headache, Fatigue, Diarrhea, Nausea, Cough, Lowered blood pressure, electrolyte imbalance
Remarks: May damage the unborn child.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity
Components:
Lisinopril:
Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 20,000 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Persistence and degradability
No data available

Bioaccumulative potential
No data available
SAFETY DATA SHEET

Lisinopril Formulation

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards
- Combustible dust
- Reproductive toxicity
- Specific target organ toxicity (single or repeated exposure)

SARA 313
- This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SAFETY DATA SHEET

Lisinopril Formulation

US State Regulations

Pennsylvania Right To Know

California Prop. 65
WARNING: This product can expose you to chemicals including Lisinopril, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average
**SAFETY DATA SHEET**

**Lisinopril Formulation**

**Version**: 6.2  
**Revision Date**: 09/13/2019  
**SDS Number**: 50025-00014  
**Date of last issue**: 04/24/2019  
**Date of first issue**: 01/26/2015

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision Date</td>
<td>09/13/2019</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8